34% overall response rate in 79 evaluable patients with measurable disease 9.1 months median duration of response Tumor reduction in 70% of patients Zeno observed to be very well-tolerated Potential new standard of care for patients with NRG1+ cancer Investor call to discuss clinical results on

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , June 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., President, Chief

- Robust 34% overall response rate and 9.1 months median duration of response across multiple NRG1+ tumor types - Zenocutuzumab observed to be well-tolerated - Oral presentation with additional patient data at ASCO on June 5, 2022 , 9:45 -11:15 a.m. CT - Investor call to discuss clinical results on

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., President, Chief

- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting -   Company to host investor call on Sunday, June 5 at 6:00 p.m. CT - Clinical data update of petosemtamab (Peto) and MCLA-129 planned for second half of 2022

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , April 27, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , April 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced

– MCLA-129 promotes Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) of non-small cell lung cancer (NSCLC) cells – MCLA-129 significantly inhibits growth of a patient-derived EGFR exon20 insertion (exon20ins) tumor in a preclinical

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , April 06, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg , M.D., President, Chief

- The poster details the mechanism of action of MCLA-129 in vitro and effectiveness in vivo in an EGFR exon20 insertion (ex20ins) non-small cell lung cancer (NSCLC) model UTRECHT, The Netherlands and CAMBRIDGE, Mass. , March 08, 2022 (GLOBE NEWSWIRE) -- Merus N.V.

As of February 2022 , more than 100 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy Clinical data updates planned for lead program Zeno in 1H22 and for petosemtamab (“MCLA-158”) and MCLA-129 in 2H22 Based on the Company’s current

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Feb. 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., President, Chief

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the